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Abstract In the past decades, synthetic biology has
gained interest regarding research and development efforts
within the biotechnology domain. However, it is unclear to
what extent synthetic biology has matured already into
being commercially exploitable. By means of a patent
analysis, this study shows that there is an increasing trend
regarding synthetic biology related patent applications. The
majority of retrieved patents relates to innovations facili-
tating the realisation of synthetic biology through improved
understanding of biological systems. In addition, there is
increased activity concerning the development of synthetic
biology based applications. When looking at potential
application areas, the majority of synthetic biology patents
seems most relevant for the medical, energy and industrial
sector. Furthermore, the analysis shows that most activity
has been carried out by the USA, with Japan and a number
of European countries considerably trailing behind. In
addition, both universities and companies are major patent
applicant actor types. The results presented here form a
starting point for follow-up studies concerning the
identification of drivers explaining the observed patent
application trends in synthetic biology.
Keywords Synthetic biology  Patent analysis 
Emerging technologies  Innovation dynamics
Introduction
Within life sciences, the concept of synthetic biology has
gained interest over the past decade due to its believed
potential to improve biotechnology-based translational
applications (Burbelo et al. 2010). Its transformation from
a philosophical construct towards a real discipline has led
to awareness among stakeholders in a position to influence
or become affected by synthetic biology’s diffusion into
society. However, in spite of its expansion over the past
decade, a lack of specific market-based studies limits the
potential to properly assess synthetic biology’s progress
regarding R&D and market penetration attempts.
A number of science and technology indicators can be
applied to asses technological progress, including patent
statistics (Hinze and Schmoch 2004). Patent indicators can
be used for a number of reasons (ibid.). First of all, patent
indicators can be considered early signals for future com-
mercial applications. Due to the general underlying costly
and time-consuming nature of patent application, patent
statistics indicate a certain amount of optimism or expec-
tation concerning described features within patents show-
ing economic potential (Basberg 1987). Secondly, patent
analysis can be valuable in analysing technology devel-
opment in relation to competition between sectors or
countries (Liu and Shyu 1997). Thirdly, based on assess-
ments of current technology trends, patent analyses can be
used in planning technology oriented national strategies
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(Abraham and Moitra 2001). Finally, patent analysis data
can be used in modelling practices concerning market
development of emerging technologies (Ashton and Sen
1988).
Innovation research based on patent analyses seems to
indicate that emerging technologies generate specific pat-
terns. Traditionally, patent development within specific
sectors was believed to follow an S-shaped pattern (Liu and
Shyu 1997). A more recent study, based on analyses of
over 40 different science-based emerging technologies,
expanded this pattern by identifying the following phases
(Schmoch 2007):1
1. An initial start of mainly experimentation and knowl-
edge gain
2. Increased development of R&D once commercial
exploitability has been reached
3. Disillusionment of industry as a result of being non-
competitive compared to alternative technologies on
industrial scale
4. Regained interest of industry, as a result of being
competitive compared to alternative technologies on
industrial scale
5. Decreasing patent applications as a result of field
saturation of the technology
Regarding this model, analysing patent trends of syn-
thetic biology could provide valuable information in what
developmental phase synthetic biology could be placed.
Furthermore, a patent analysis provides an opportunity to
perform cross-country comparisons regarding patent filing
dynamics. In addition, a patent analysis could assist in the
identification of actors and organisations active in synthetic
biology. Finally, the analysis of synthetic biology patents
could provide more detailed knowledge concerning the
nature, presence and temporal development of translational
synthetic biology patent applications.
The contribution of this paper is twofold. First, a
methodological approach is presented for analysing pat-
enting activities in synthetic biology. One of the difficulties
in performing patent analyses for emerging technologies
relates to their unspecific classification within the interna-
tional patent classification (IPC). Due to potential ‘group-
overlapping’ nature of emerging technology patent content,
such patents are in general classified under multiple
existing groups. Therefore, patent content analysis is
required to identify emerging technology patents within the
IPC. This paper presents a methodology, based on both the
IPC and patent content, which can be applied to extract
patent applications related to synthetic biology. The second
contribution of this paper is the identification of patent
application trends within synthetic biology. Based on the
applied patent analysis approach, the retrieved patent col-
lection has been used to perform several analyses with
respect to cross-country comparisons, actor identification
and sector relevant patenting dynamics.
Methods
This patent analysis contains the following steps:
• Step 1: Setting technology independent search criteria
Patents can be filed on both national and international
level. Search criteria are set to define in which patent
office patents will be searched for. In addition, the time-
frame is set to limit the years of patent applications that
will be included in the final patent search.
• Step 2: Develop a technology dependent search strat-
egy The search strategy is developed based on (a) patent
content (keywords, keyword-combinations, keyword-
strings), and (b) the IPC.
• Step 3: Retrieve patents Based on the developed search
strategy, international patent databases are queried;
retrieved patents are then examined on relevance for the
field of synthetic biology.
• Step 4: Analysing patents Based on the retrieved
synthetic biology patent-pool, a number of analyses
are made, including (1) comparative cross-country
analysis, (2) actor analysis, (3) sector analysis, and
(4) content analysis.
Step 1: Setting technology independent search criteria
Patent office
For the patent search, the World Intellectual Property
Organization (WIPO) has been set as inclusive filter cri-
teria. The selection of patents filed directly to this inter-
national patent office is due to three reasons. First of all,
WIPO patents are regarded as being subjected to high
application standards. Secondly, the international nature of
WIPO patent applications enhances international compar-
ison due to standardised patent filing conditions and cri-
teria,2 thereby avoiding the introduction of statistical bias
related to national patent office conditions and character-
1 The resulting pattern was labelled as representing ‘‘double-boom
cycles’’.
2 Patent applications at WIPO fall under the PCT (Patent Classifi-
cation Treaty). The PCT is an international treaty, administered by the
World Intellectual Property Organization (WIPO), between more than
140 Paris Convention countries (http://www.wipo.int/pct/en/faqs/
faqs.html), including the most active European, Asian and North-
and South-American countries.
210 D. van Doren et al.
123
istics.3 Finally, patents filed at international patent offices,
in comparison to applications at national offices, indicate a
relative high economic and global potential of its described
invention. The European Patent Office (EPO), another
important international patent office, has been left out in
order to avoid a potential bias towards European inventors.
Since only WIPO patents were retrieved and analysed, the
inclusion of potential multiple patent applications within
identical patent families was eliminated.
Time-scale
Due to the institutionalised structure of patent processing,
patent applications are in general published 18 months
after the earliest priority date of patent application. This
time-lag, in combination with the dated database of the
main patent search engine (PATSTAT, database September
2012), the year 2010 is the most recent year with a com-
plete coverage of filed patents. In order to acquire a historic
perspective on patent trend development of the synthetic
biology field, patents filed in the period 1990–2010 were
selected for final analysis.
Step 2: Develop a technology dependent search strategy
Selection of keywords, keyword-strings and keyword-
combinations
For synthetic biology, the identification of suitable key-
words is problematic. As it is still not agreed among
experts how to exactly define synthetic biology, the iden-
tification of proper keywords is challenging.
Keywords have been identified, selected and categorised
based on an existing framework developed to position
synthetic biology within the field of biotechnology.4 This
three-dimensional biotechnology framework, based on the
identification of drivers relevant for historic biotechnology
development, explains the emergence of synthetic biology
through the interplay of three distinct drivers, being (1)
understanding biological systems, (2) technological reso-
lution, and (3) engineering principles. The framework’s
rationale has been used as a starting point for finding
suitable keywords. The translation of the framework’s
rationale into a patent search strategy was executed into
three separate parts:
• Part 1: Knowledge generation and engineering Key-
words that indicate important facets at different levels
of biological systems (Young and Alper 2010); (Rollie´
et al. 2011) were selected; terms for the objects of
biotechnology were combined with terms that indicate
the realization of the guiding principles relevant in the
synthetic biology research area, including the engi-
neering principles of standardisation, decoupling and
abstraction.
• Part 2: Enabling technologies of synthetic biology
Keywords that indicate enabling technologies, that are
believed to be crucial for the maturing of synthetic
biology or for the realisation of the guiding principles,
were selected.
• Part 3: Applications of synthetic biology Keywords that
indicate potential applications of synthetic biology
were selected.
The keywords have been identified and characterised by
means of a qualitative literature analysis, including review
articles and other secondary documents.
Selection of IPC-(sub) classes and (sub) groups
The IPC consists of five different aggregation levels (http://
www.wipo.int/classifications/ipc/en/):
• Level 1 Section; for example Section C chemistry and
metallurgy
• Level 2 Class; for example Class C12 biochemistry;
beer; spirits; wine; vinegar; microbiology; enzymology;
mutation or genetic engineering
• Level 3 Subclass; for example Subclass C12N micro-
organisms or enzymes; compositions thereof
• Level 4 Group; for example Group C12N1 micro-
organisms, e.g. protozoa; compositions thereof
• Level 5 Subgroup; for example Subgroup C12N1/21
bacteria; culture media therefore modified by introduc-
tion of foreign genetic material
Descriptions of all sections, (sub) classes and (sub)
groups within the IPC have been reviewed for synthetic
biology relevance (http://www.wipo.int/classifications/ipc/
en/). IPC sections, (sub) classes and/or (sub) groups were
included into the strategy when at least one of the three
dimensions of the applied synthetic biology framework was
identified within their description.
Step 3: Retrieve patents
Combinations of selected IPC-(sub) classes/(sub) groups
with obtained keywords (combinations/strings) were sear-
ched for within three patent databases: (1) DERWENT
World Patents Index (http://thomsonreuters.com/ products_
services/legal/legal_products/a-z/derwent_world_patents_
index/), (2) Espacenet (http://worldwide.espacenet.com/
3 One example of such bias is the exclusion of patents filed in distant
languages using different symbols (Asian, Russian, Arabic).
4 Forthcoming book chapter for the Edward Elgar Series on Science,
Technology, Innovation and Entrepreneurship, in progress. See also
van Doren and Reiss 2012.
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advancedSearch?locale=en_EP), and (3) EPO Worldwide
Patent Statistical Database (PATSTAT, Version September
2012; see also http://www.epo.org/searching/subscription/
raw/product-14-24.html-PATSTAT queries were con-
ducted with Oracle SQL*Plus).
Combinations were searched for in both patent titles and
abstracts. Abstracts of search hits were analyzed regarding
their relevance to the field of synthetic biology as described
by the applied framework. Ambiguous search terms
resulting in false positive hits were identified and adjusted
accordingly in order to improve the overall result rele-
vance. The PATSTAT database was used to retrieve the
final patent-pool that was subsequently used for analyses.
In Table 1, the final search strategy is listed. The strat-
egy is developed in three parts as discussed in Step 2 of the
methodology. Patents have been retrieved based on both
the complete strategy and its individual parts.
Step 4: Analysing patents
Selection of countries
In this study, the total amount of filed patents, or growth
curve, has been used to estimate the development of the
field synthetic biology (1) in general, and (2) a selection of
countries (Bengisu and Nekhili 2006). All countries were
Table 1 Strategy patent analysis synthetic biology, divided into three parts representing the three dimensions of the field. The asterisk (*) is a
wildcard character that matches any occurrence of 0 or more characters
Strategy part IPC classes Keywords, string and combinations
Strategy part 1: Knowledge generation and





Keywords: riboswitch* Strings: synthetic biology; synthetic amino
acid; synthetic base pair; synthetic genome; synthetic genet*;
synthetic nucleic acids; synthetic *nucleotide; synthetic
sequence; artificial amino acid; artificial base pair; artificial
genome; artificial genet*; artificial nucleic acids; artificial
*nucleotide; artificial sequence; genetic circuit; signalling
pathway; systems biology; metabolic engineering; synthetic
protocell; synthetic cell; artificial cell; minimal cell; cell chassis;
vesicul* bioreactor; vesicle bioreactor; minimal genome;
synthetic gene cluster; synthetic regulatory network; gene circuit
design; biological parts; dna assembly; rational protein design;
computational protein design; de novo enzyme design;
noncanonical amino acid; unnatural amino acid; rna design;
rational design; dna origami; rna nanostructure*; dna
nanostructure*; gene* switch; synthetic gene network; artificial
gene network; genome engineering; gene oscillator; synthetic
shRNA; artificial shRNA; heterologous nucleic acid; biological
circuit Combinations: molecular machine AND protein;
molecular machine AND bio; RNA AND computational design;
RNA AND rational design





Keywords: cad; cam; microfluidics Strings: design platform;
computer aided design; systems biology model*; metabolomic*
model*; transcriptomic* model*; protein folding model*;
protein folding prediction; RNA folding model*; RNA folding
prediction; multiplex ligation; multiple amplification; dna
synthesis; gene synthesis Combinations: multiplex AND
genome; multiplex AND gene
Strategy part 3: Applications of synthetic biology C12N; C12P;
C12Q; C12S;
C40B
Combinations: smart material AND bacter*; fuel AND bacter*;
energy AND bacter*; medicine AND bacter*; photosynth* AND
bacter*; nano* AND bacter*; nano AND bacter*; industr* AND
bacter*; remediation AND bacter*; smart material AND
microbio*; fuel AND microbio*; energy AND microbio*;
medicine AND microbio*; photosynth* AND microbio*; nano*
AND microbio*; nano AND microbio*; industr* AND
microbio*; remediation AND microbio*; smart material AND
microbia*; fuel AND microbia*; energy AND microbia*;
medicine AND microbia*; photosynth* AND microbia*; nano*
AND microbia*; nano AND microbia*; industr* AND
microbia*; remediation AND microbia*
C12N; C12P;
C12Q; C12S
Combinations: environment AND degradation
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included in the patent search. Since patents can be filed by
multiple applicants from different countries, patents were
accordingly weighted regarding the involved nationalities
of patent applicants.5
In addition, two normalisation calculations were per-
formed. First, in order to correct for country population, the
amount of patent application per million capita was cal-
culated (Reiss and Lacasa 2008).6 And second, in order to
assess the relative growth of synthetic biology patent
applications within total WIPO patent applications, the
proportion of synthetic biology patents in relation to the
total amount of WIPO patent applications was determined.
These proportions were accordingly normalised with ref-
erence year 1990. Total amounts of WIPO patent appli-
cations for the period 1990–2010 were identified by means
of PATSTAT query.
Analysis of both content and application domains
of synthetic biology
In order to gain insight regarding the nature of synthetic
biology applications, patents retrieved by means of one
specific search strategy part (part 3: applications of syn-










Categorisation has been based on both quantitative
analyses and qualitative expert-judgement according to a
two-step process. First, a pre-categorisation was made
based on the applied search terms. In addition, the final
categorisation of patents was made based on patent title
and patent abstract. After categorisation, keyword searches
related to the established categories were made to catego-
rise the individual retrieved patents.
Analysing actors in synthetic biology
Based on the retrieved patent-pool, synthetic biology patent
applicants have been identified. Weighted patent
applications were used to identify the top-20 most active
patent filers. These major applicants were categorised to
obtain insights concerning their institutional background.
The following applicant categorisation has been made:
• Company
• University and college
• Individual
• Research institute
Analysis of synthetic biology patents in the IPC
Retrieved patents have also been analysed according to
how they have been placed within the IPC. As a result of
how the IPC is managed and updated, emerging technol-
ogies do often not have a dedicated location within this
system. In order to obtain insights regarding patentable
domains relevant for synthetic biology, the IPC locations of
retrieved patents were analysed.
Results
Global synthetic biology activity
Based on the applied patent analysis methodology, a total
of 1,195 patents was retrieved (Figs. 1, 2). The number of
retrieved patents per year is low, not exceeding 95 patents
per year. Nevertheless, the analysis shows a clear increase
in filed patents over the last 20 years. In 1990, only 13
patents were filed, whereas in 2010 a total of 86 patents
were filed. The maximum of patents filed in one year was
95 in 2007, whereas the minimum of patents filed in one
year was 8 in 1991.
The USA shows most activity in synthetic biology pat-
ent filing, showing an increase from 8.0 (1990) to a total of
35.1 (2008) patents filed by USA applicants. Over the















































USA Japan Germany United Kingdom
France Canada South Korea Australia
Russia Spain Netherlands Denmark
Switzerland China Italy Rest of World
Fig. 1 Trend of patent applications in the period 1990-2010: Top-15
countries and rest of world
5 For example, when patent x was filed by applicant A from USA and
applicant B from Germany, both applicants receive 1/2 of the co-
applied patent. As a result, final analyses regarding patent amounts
can contain fractions.
6 Source country population data: http://www.nationsonline.org/
oneworld/population-by-country.htm.
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1,195 retrieved patents. Trailing behind the USA, Japan
(103.8 patents) and Germany (81.6 patents) show also
significant patent filing activity. Germany (from 1 patent in
1990 to 6.2 patents in 2010) and Japan (from 0 patents in
1990 to 6.0 patents in 2010) also show the largest relative
increase in patent application. Other countries showing
considerable activity (at least more than 50 patents in
1990–2010) are United Kingdom (64.2 patents) and France
(58.8 patents).
Relative to country population size, minor shifts
regarding country ranking with respect to synthetic biology
patent applications are observed (Fig. 3). Although the
USA still ranks high, it is overtaken by the relative low
population European countries Denmark and Switzerland
regarding the highest density of synthetic biology patent
applicants. Other relative low population countries
including Australia and the Netherlands also rank higher,
whereas relative high population countries including Japan
and Russia rank considerably lower.
When analysing the proportion of synthetic biology
patent applications in relation to total annual WIPO patent
applications, we observe an increase of proportion in the
period 1991–2001 (Fig. 4). From 2002 onwards, this pro-
portion decreases again towards a comparable proportion
of synthetic biology patent applications with respect to the
reference year 1990.
Nature of synthetic biology trends
Besides the complete strategy, parts of the strategy have
been used for searches reflecting the development of the
different dimensions of synthetic biology (Fig. 5).
The patenting trend related to knowledge and engi-


































Fig. 2 Patent applications for synthetic biology: Share of top-15


















































Fig. 3 Synthetic biology patent applications of top-15 countries per
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Fig. 4 Annual WIPO patent applications and the proportion of







































Knowledge Enabling technologies Applications
Fig. 5 Overview of individual strategy parts: (part 1) knowledge and
engineering of synthetic biology, (part 2) enabling technologies of
synthetic biology, and (part 3) applications of synthetic biology
(part 3)
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in comparison with the overall strategy. The overall trend
for this strategy part is increasing from 8 patents filed in
1990 to 40 patents filed in 2010. The maximum amount of
patents filed is 51 in 2007; the minimum amount of patents
filed is 5 in 1991. It is apparent that research regarding
improved understanding of biological systems has not
decreased in importance over the last 20 years. This indi-
cates that basic research is still highly important to develop
the synthetic biology field.
Patent applications regarding enabling technologies of
synthetic biology (part 2) show a somewhat different pat-
tern. In general, patent filing activity shows an increase from
3 (1990), with an intermediate peak in 2002 (15 patents), to
22 patents being filed in 2005. From 2005 onwards, there is a
decline towards 2 patents filed in 2009. However, patent
application activity regarding synthetic biology enabling
technologies increases again in 2010 (10 patents).
The patenting trend regarding applications of synthetic
biology (part 3) indicates increasing patent filing activity
over the whole analysed period. First signs of considerable
activity start to emerge around 1997. From 1997 onwards,
patent filing activity increases towards a peak of 39 patents
in 2009.
Synthetic biology actors
A total of 3,988 different applicants were involved in filing
the 1,195 retrieved synthetic biology patents. Of these
3,988 applicants, the 20 most active applicants filed more
than 2 patents (weighted value with respect to the amount
of applicants per patent application) (Table 2; Fig. 6).
Concerning the institutional background of patent appli-
cants, the majority originates from companies.
The most active synthetic biology applicant is the Uni-
versity of California, holder of the synthetic biology
institute in Berkeley. An equally active synthetic biology
patent applicant is Hybridon, a biotechnology company
based in Cambridge (Massachusetts). Hybridon, who
merged with Idera Pharmaceuticals in 2004, concentrates
on the development of therapeutics and diagnostics using
synthetic DNA. Most active individual patent applicant in
the period 1990–2010 was Peter Schultz, who is conduct-
ing basic research related to molecular biological building
blocks at the Scripps Research Institute in San Diego,
California. Ronald Breaker, another active individual pat-
ent applicant, performs fundamental research at Yale
University in New Haven concerning structures and func-
tions of RNA and DNA molecules.
Synthetic biology application areas
Many of the retrieved patents have a strong focus towards
both engineered biological parts and the methodology to
analyse and produce these. Topics of such focus include
DNA synthesis and sequencing methods, evolutionary
approaches to construct artificial nucleotide sequences, the
production of selective growth cultures, understanding of
processes related to cell metabolism, the development of
test-systems, and methods related to multiplication,
expression and nucleic acid modelling.
When looking at relevant application areas regarding
synthetic biology patents (strategy part 3 applications of
synthetic biology), the large majority seems most relevant
for industrial biotechnology (38.4 % of in total 391 pat-
ents) (Fig. 7). A patent share of 13.8 % seems most rele-
vant for the medical domain. One focus of patents related
to medical application includes neural DNA-injection and
the production of potentially active pharmaceutical com-
ponents for a wide variety of medical indications, including
nucleic acids, peptides and proteins. Another focus of
medical patent applications concerns the unravelling of
disease mechanisms and the role of signal transduction
therein. Patents relevant for energy production (11.8 %)
seem to focus on dominant themes including hydrogen
Table 2 Overview patent applicants








Hybridon, Inc. 6.6 Company
Yale University 4.8 University
and college
Novo Nordisk a/s 4.2 Company






Agritope, Inc. 3.3 Company
Avigenics, Inc. 3.2 Company
Board of Regents, the
University of Texas system
3.1 University
and college












Ronald Breaker R. 2.3 Individual
Dsm ip Assets B.V. 2.3 Company
Genencor International, Inc. 2.2 Company
Degussa AG 2.2 Company
Baylor College of Medicine 2.2 University
and college
Novozymes A/S 2.1 Company
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production, photosynthesis process enhancements and
feedstock production improvements.
Concerning the chronological development of synthetic
biology patents, it seems that especially application
domains related to fuels, nanotechnology and environ-
mental remediation have received increased attention over
the past decades (Fig. 8).
IPC classification of synthetic biology patents
Class C12 (Biochemistry) is by far the most prominent
class in which synthetic biology patents are being catego-
rised (Fig. 9; Table 3). Concerning this categorisation,
C12Q 1/68 (measuring or testing processes involving
nucleic acids) is the most dominant IPC subgroup within
the C12 class (Fig. 10).
Discussion
Main findings
This analysis does not intend to provide full explanations
of the observed trends in patent development within the
field of synthetic biology. In order to compare the activities
of different countries in more detail, a deeper analysis into
drivers of national innovation performance is required.
Furthermore, it is not clear to what extent a patent analysis
suffices in giving a comprehensive representation of syn-
thetic biology’s development. Patent statistics is only one
of many available science and technology indicators that
can be applied to assess development of the synthetic
biology sector. Accordingly, analyses of the retrieved
patent data, including derived conclusions regarding the
patent analyses, should be interpreted with care.
Taking these limitations into account, the presented































Fig. 7 Division of synthetic biology patent applications, in the period
1990–2010, according to their application area. Based on part 3









































Industrial biotechnology Medicine Energy
Chemical Fuel Nanotechnology
Environmental remediation Material
Fig. 8 Chronological overview of the absolute amount of patent
applications over different application domains. Based on strategy









Fig. 9 Relative share of synthetic biology patents regarding the
international patent classification (IPC)
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related to the development of the synthetic biology field. One
of the main outcomes is the confirmation of the prematurity
of synthetic biology in terms of patenting activity. This might
indicate that synthetic biology activities are still in an early
developmental phase, with still a large focus on exploration
through basic research.
Considering the observed patenting trends of the dif-
ferent strategy parts, some possible hypotheses regarding
their underlying drivers could be posed. Initial activity in
basic research might have fuelled patent development of
enabling technologies. Increased focus on the development
of these enabling technologies might have been stimulated
through a number of large scale research projects. The
combined effect of knowledge generation and enabling
technologies might have led to a significant increase in
developing application oriented patents around 2005
Table 3 Overview of IPC








C12N Micro-organisms or enzymes
C12P Fermentation or enzyme-using processes to synthesise a desired chemical compound or
composition or to separate optical isomers from a racemic mixture
C12Q Measuring or testing processes involving enzymes or micro-organisms





C12N 1/21 Micro-organisms—bacteria modified by introduction of foreign genetic material
C12N 5/00 Undifferentiated human, animal or plant cells






Mutation or genetic engineering
C12N
15/09
Mutation or genetic engineering—recombinant DNA-technology
C12N
15/10
Mutation or genetic engineering—recombinant DNA-technology; processes for the isolation,
preparation or purification of DNA or RNA
C12N
15/11
Mutation or genetic engineering—recombinant DNA-technology; DNA or RNA fragments
C12N
15/12
Mutation or genetic engineering—recombinant DNA-technology; DNA or RNA fragments;
Genes encoding animal proteins
C12N
15/63
Mutation or genetic engineering—recombinant DNA-technology; introduction of foreign
genetic material using vectors
C12 N
15/82
Mutation or genetic engineering—recombinant DNA-technology; introduction of foreign
genetic material using vectors; Vectors or expression systems specially adapted for
eukaryotic hosts; for plant cells
C12N
15/85
Mutation or genetic engineering—recombinant DNA-technology; Introduction of foreign
genetic material using vectors; vectors or expression systems specially adapted for
eukaryotic hosts; for animal cells
C12N
15/113
Mutation or genetic engineering—recombinant DNA-technology; DNA or RNA fragments;
non-coding nucleic acids modulating the expression of genes
C12P 3/00 Preparation of elements or inorganic compounds except carbon dioxide
C12P 19/04 Preparation of compounds containing saccharide radicals—polysaccharides
C12P 19/34 Preparation of compounds containing saccharide radicals—preparation of nitrogen-
containing carbohydrates; N-glycosides; nucleotides; polynucleotides
C12P 21/02 Preparation of peptides or proteins—having a known sequence of two or more amino acids
C12Q 1/68 Measuring or testing processes involving enzymes or micro-organisms—involving nucleic
acids
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onwards, by both existing organisations and new synthetic
biology start-ups.
In general, also in reflection of the different develop-
mental phases of emerging technologies (Schmoch 2007),
the field of synthetic biology seems to be in the first phase
of mainly experimentation and knowledge gain. Never-
theless, the increasing trend of application oriented patents
might be an indication of a gradual transition into the next
phase of commercial exploitation.
Comparing countries
The large contribution of the USA in synthetic biology
patent development might be a consequence of USA’s
history in biotechnology development in general. USA is
still by far the most active country concerning the amount
of biotechnology firms (Van Beuzekom and Arundel
2009), the development of industrial biotechnology,7 and
investments in biotechnology-based R&D.8 The dominance
of the USA is also reflected in patent applications of bio-
technology in its totality (Reiss and Lacasa 2008).
Outside the USA, there is a large impact made by Japan.
Other Asian countries showing considerable patent filing
activity include South Korea and China. China has already
shown signs of large interest in developing this field (Pei
et al. 2011); (Zhang et al. 2011). India, although not very
active yet with respect to synthetic biology patent filings,
has shown the largest relative increase in biotechnology
patents granted in the period 2000–2009 (OECD 2010).
It could be argued that the general trailing of European
countries behind USA regarding synthetic biology patent
applications may be caused by Europe’s strong historic
position within the chemical sector. However, such orien-
tation does not need to obstruct synthetic biology devel-
opments. This patent analysis has shown that Germany and
the United Kingdom, both holding the largest chemical
companies in Europe,9 are also the most active European
countries with regard to synthetic biology patent applica-
tions. The potential of biotechnology to produce chemicals,
thereby decreasing the dependence on fossil sources for
their production, might have been an incentive for these
countries to invest in synthetic biology related activities.
Nevertheless, follow-up research is required to validate the
correctness of such speculation.
Applications of synthetic biology
An increasing trend regarding application related synthetic
biology patents is observed. A large share of these patents
seems to relate to industrial biotechnology. Besides this
focus on industrial biotechnology, the interest of synthetic
biology in the medicine area is not surprising. The focus on
developing new pharmaceutics reflects present expecta-
tions concerning the potential of biotechnology in general.
This might explain the contribution of the UK in synthetic
biology patents, having shown a historic trend of applying
biotechnology in developing the pharmaceutical sector
(Boyle 2011).
There is also considerable interest in patents related to
fuel and energy production. This trend might have been
driven by renewed interest in fossil source independency,
stimulating the use biotechnology for biofuel production. In
conjunction with external data about the current production
of biofuels within Europe, this application area of synthetic
biology might become commercially viable on short term.
Large interest from leading countries like Germany, France,
Italy and Spain (EUROSTAT 2011) might indicate a certain
orientation of these countries towards the supply, transfor-
mation and consumption of biofuels.
Institutional context
When looking at the actors involved in synthetic biology
patenting, it can be observed that mainly leading univer-
sities, relatively new synthetic biology specific companies
and a number of multinational companies are active. The
involvement of novel innovative synthetic biology com-
panies might have been driving forces for the development
of synthetic biology. The involvement of longer existing
large multinational companies could be explained with the
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Fig. 10 Amount of weighted entries of the top-20 IPC-classes
7 Published by FAZ (2008). Used sources include Coston Consulting
Group (BCG), Bio Deutschland, EMEA, Ernst & Young, European
Commission, FAZ-Archive, Companies and VFA.
8 Published by Ernst and Young (2010). The pharmaceutical industry
in figures.
9 Based on data derived from Amadeus (2011): see https://amadeus.
bvdinfo.com/version-2012104/home.serv?product=amadeusneo.
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of medicine and chemistry, sectors which are dominated by
traditional large companies. The patenting activity of these
large companies could also indicate their high expectations
concerning the future potential of synthetic biology.
Limitations of the study
Within this study, there are a number of limitations that
need to be mentioned.
One limitation lies within the relative low amount of
retrieved patents. Although this amount could reflect the
developmental state of the field, it introduces a large
influence of noise, hampering interpretation of the strat-
egy’s output. It is therefore difficult to judge to what extent
fluctuations in the observed trends are real changes of
activity related to synthetic biology, or merely artefacts of
present noise.
A second limitation of this analysis is the lack of
qualitative indices for patent strength, including citation-
indices or regression models. Citation-indices can be used
to (1) indicate the importance of a patent for other patents,
or (2) to describe the relationships between patents or their
developers through the visualisation of citation networks
(Brinn et al. 2003). Regression models can be used to
analyze the relationship between (1) patent development,
and (2) R&D spending at the firm level (Wang et al. 1998).
However, the relative low amount of patent application of
synthetic biology limits the extent statistical tools can be
used to create a more robust picture.
A third limitation concerns the development of the
overall strategy. Although the applied search criteria have
arguably facilitated the retrieval of synthetic biology rele-
vant patents, they also limit the absolute scope of a patent
search. As a result, synthetic biology relevant patents that
are hard to identify by means of specific search criteria
might have been unintentionally excluded from the anal-
ysis. Although this is a general limitation within the
applied methodological approach, it limits the abstraction
of conclusions regarding the absolute developmental state
of the synthetic biology field. In addition, due to the het-
erogeneous collection of present synthetic biology per-
ceptions, defining a strategy that could be agreed upon
unanimously is challenging. This issue was addressed in
the strategy by integrating the suggested three fundamental
drivers for the development of synthetic biology. Although
the applied framework seems to be a valid representation of
current discussions concerning delineation of the synthetic
biology, this analysis should be regarded as a particularly
and temporary interpretation of this emerging field.
A final limitation regards to what extent the observed
patent dynamics represent comprehensively and com-
pletely research, development and market activities for
emerging technologies. Especially in the synthetic biology
domain, there is considerable discussion regarding the
appropriateness of alternative strategies with regard to
intellectual property management (e.g., see Henkel and
Maurer 2009). Standardisation, open source and collabo-
ration oriented business model innovation might already
influence the role and value of synthetic biology patent
applications. Therefore, the results obtained through this
study should be interpreted as a partial representation
regarding synthetic biology developments.
Further research
The main aim of this research was to provide a meth-
odological approach to identify synthetic biology patents.
Based on the developed methodological approach, iden-
tified patent applications were analysed to enable insights
regarding the dynamic, nature and actor specificity within
the field of synthetic biology. These dynamics could serve
as a foundation for future research in explaining and
identifying both technological and non-technological
factors driving the observed synthetic biology patent
activity.
The provided analysis provides some initial indications
and nation-based trends concerning the development of the
emerging field synthetic biology. However, this paper does
not provide answers for all observed phenomena within the
analysis. Further research is required to provide explana-
tions concerning the nature of underlying drivers for these
phenomena and the validity of the proposed potential
explanations.
And finally, the analysis of technology trends alone
cannot incorporate the organizational and political sce-
narios that will influence the development and direction of
future technologies (Daim et al. 2006). A deeper investi-
gation into potential drivers of innovation, including pro-
cesses underlying market regulation and social acceptance,
could facilitate deeper insight of key actor behaviour. Such
analyses could provide improved understanding with
respect to the observed patent trends in synthetic biology.
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